Literature DB >> 21930876

Fluoroquinolone efflux in Streptococcus suis is mediated by SatAB and not by SmrA.

Jose Antonio Escudero1, Alvaro San Millan, Belen Gutierrez, Laura Hidalgo, Roberto M La Ragione, Manal AbuOun, Marc Galimand, María José Ferrándiz, Lucas Domínguez, Adela G de la Campa, Bruno Gonzalez-Zorn.   

Abstract

Streptococcus suis is an emerging zoonotic pathogen. With the lack of an effective vaccine, antibiotics remain the main tool to fight infections caused by this pathogen. We have previously observed a reserpine-sensitive fluoroquinolone (FQ) efflux phenotype in this species. Here, SatAB and SmrA, two pumps belonging to the ATP binding cassette (ABC) and the major facilitator superfamily (MFS), respectively, have been analyzed in the fluoroquinolone-resistant clinical isolate BB1013. Genes encoding these pumps were overexpressed either constitutively or in the presence of ciprofloxacin in this strain. These genes could not be cloned in plasmids in Escherichia coli despite strong expression repression. Finally, site-directed insertion of smrA and satAB in the amy locus of the Bacillus subtilis chromosome using ligated PCR amplicons allowed for the functional expression and study of both pumps. Results showed that SatAB is a narrow-spectrum fluoroquinolone exporter (norfloxacin and ciprofloxacin), susceptible to reserpine, whereas SmrA was not involved in fluoroquinolone resistance. Chromosomal integration in Bacillus is a novel method for studying efflux pumps from Gram-positive bacteria, which enabled us to demonstrate the possible role of SatAB, and not SmrA, in fluoroquinolone efflux in S. suis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930876      PMCID: PMC3232752          DOI: 10.1128/AAC.00498-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Stimulating the development of national Streptococcus suis guidelines in Viet Nam through a strategic research partnership.

Authors:  Peter Horby; Heiman Wertheim; Nguyen Hong Ha; Nguyen Vu Trung; Dao Tuyet Trinh; Walter Taylor; Nguyen Minh Ha; Trinh Thi Minh Lien; Jeremy Farrar; Nguyen Van Kinh
Journal:  Bull World Health Organ       Date:  2010-01-26       Impact factor: 9.408

Review 2.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Different genetic elements carrying the tet(W) gene in two human clinical isolates of Streptococcus suis.

Authors:  Claudio Palmieri; Maria Stella Princivalli; Andrea Brenciani; Pietro E Varaldo; Bruna Facinelli
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

5.  The genome of Streptococcus pneumoniae is organized in topology-reacting gene clusters.

Authors:  María-José Ferrándiz; Antonio J Martín-Galiano; Jorge B Schvartzman; Adela G de la Campa
Journal:  Nucleic Acids Res       Date:  2010-02-21       Impact factor: 16.971

6.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

7.  The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.

Authors:  Mark I Garvey; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

8.  Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.

Authors:  Alvaro San Millan; Jose Antonio Escudero; Belen Gutierrez; Laura Hidalgo; Nerea Garcia; Montserrat Llagostera; Lucas Dominguez; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

9.  Streptococcus suis meningitis without history of animal contact, Italy.

Authors:  Aldo Manzin; Claudio Palmieri; Corrado Serra; Barbara Saddi; Maria Stella Princivalli; Giovanni Loi; Giuseppe Angioni; Franco Tiddia; Pietro E Varaldo; Bruna Facinelli
Journal:  Emerg Infect Dis       Date:  2008-12       Impact factor: 6.883

10.  Rapid evolution of virulence and drug resistance in the emerging zoonotic pathogen Streptococcus suis.

Authors:  Matthew T G Holden; Heidi Hauser; Mandy Sanders; Thi Hoa Ngo; Inna Cherevach; Ann Cronin; Ian Goodhead; Karen Mungall; Michael A Quail; Claire Price; Ester Rabbinowitsch; Sarah Sharp; Nicholas J Croucher; Tran Bich Chieu; Nguyen Thi Hoang Mai; To Song Diep; Nguyen Tran Chinh; Michael Kehoe; James A Leigh; Philip N Ward; Christopher G Dowson; Adrian M Whatmore; Neil Chanter; Pernille Iversen; Marcelo Gottschalk; Josh D Slater; Hilde E Smith; Brian G Spratt; Jianguo Xu; Changyun Ye; Stephen Bentley; Barclay G Barrell; Constance Schultsz; Duncan J Maskell; Julian Parkhill
Journal:  PLoS One       Date:  2009-07-15       Impact factor: 3.240

View more
  11 in total

1.  SatR is a repressor of fluoroquinolone efflux pump SatAB.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Natalia Montero; Belen Gutierrez; Cristina Martinez Ovejero; Laura Carrilero; Bruno González-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  Highly Tigecycline-Resistant Klebsiella pneumoniae Sequence Type 11 (ST11) and ST147 Isolates from Companion Animals.

Authors:  Cristina M Ovejero; Jose Antonio Escudero; Daniel Thomas-Lopez; Andreas Hoefer; Gabriel Moyano; Natalia Montero; Carmen Martin-Espada; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 3.  Mechanisms of drug resistance: quinolone resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Ann N Y Acad Sci       Date:  2015-07-17       Impact factor: 5.691

Review 4.  Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

5.  Genome sequences of antibiotic-resistant Streptococcus suis strains isolated from human patients and diseased and asymptomatic pigs in Thailand.

Authors:  Suganya Yongkiettrakul; Thidathip Wongsurawat; Piroon Jenjaroenpun; Daniel A Acheampong; Potjanee Srimanote; Krissana Maneerat; Wonnop Visessanguan; Intawat Nookaew
Journal:  Infect Genet Evol       Date:  2020-12-13       Impact factor: 3.342

6.  Streptococcus suis, an Emerging Drug-Resistant Animal and Human Pathogen.

Authors:  Claudio Palmieri; Pietro E Varaldo; Bruna Facinelli
Journal:  Front Microbiol       Date:  2011-11-25       Impact factor: 5.640

7.  PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Haseeb Khaliq; Jiyue Cao; Qigai He
Journal:  Front Pharmacol       Date:  2017-11-20       Impact factor: 5.810

8.  Patterns of antimicrobial resistance in Streptococcus suis isolates from pigs with or without streptococcal disease in England between 2009 and 2014.

Authors:  Juan Hernandez-Garcia; Jinhong Wang; Olivier Restif; Mark A Holmes; Alison E Mather; Lucy A Weinert; Thomas M Wileman; Jill R Thomson; Paul R Langford; Brendan W Wren; Andrew Rycroft; Duncan J Maskell; Alexander W Tucker
Journal:  Vet Microbiol       Date:  2017-06-13       Impact factor: 3.293

9.  Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to Streptococcus pseudopneumoniae.

Authors:  María Alvarado; Antonio J Martín-Galiano; María J Ferrándiz; Ángel Zaballos; Adela G de la Campa
Journal:  Front Microbiol       Date:  2017-10-26       Impact factor: 5.640

10.  The GAS PefCD exporter is a MDR system that confers resistance to heme and structurally diverse compounds.

Authors:  Ankita J Sachla; Zehava Eichenbaum
Journal:  BMC Microbiol       Date:  2016-04-19       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.